

Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles

Tijms, Betty M.; Vromen, Ellen M.; Mjaavatten, Olav; Holstege, Henne; Reus, Lianne M.; van der Lee, Sven; Wesenhagen, Kirsten E.J.; Lorenzini, Luigi; Tesi, Niccoló; More Authors

DOI

[10.1038/s43587-023-00550-7](https://doi.org/10.1038/s43587-023-00550-7)

Publication date

2024

Document Version

Final published version

Published in

Nature Aging

Citation (APA)

Tijms, B. M., Vromen, E. M., Mjaavatten, O., Holstege, H., Reus, L. M., van der Lee, S., Wesenhagen, K. E. J., Lorenzini, L., Tesi, N., & More Authors (2024). Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles. *Nature Aging*, 4(1), 33-47. <https://doi.org/10.1038/s43587-023-00550-7>

Important note

To cite this publication, please use the final published version (if applicable).
Please check the document version above.

Copyright

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Takedown policy


Please contact us and provide details if you believe this document breaches copyrights.
We will remove access to the work immediately and investigate your claim.











Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles

Received: 11 September 2023

Accepted: 29 November 2023

Published online: 09 January 2024

 Check for updates

Betty M. Tijms ^{1,2}✉, Ellen M. Vromen^{1,2}, Olav Mjaavatten³, Henne Holstege ^{1,2,4}, Lianne M. Reus^{1,2,5}, Sven van der Lee ^{1,2,6}, Kirsten E. J. Wesenhagen^{1,2}, Luigi Lorenzini^{7,8}, Lisa Vermunt ^{2,9}, Vikram Venkatraghavan^{1,2}, Niccoló Tesi ^{6,10}, Jori Tomassen^{1,2}, Anouk den Braber^{1,2,11}, Julie Goossens¹², Eugeen Vanmechelen ¹², Frederik Barkhof ^{7,13}, Yolande A. L. Pijnenburg^{1,2}, Wiesje M. van der Flier ^{1,2,14}, Charlotte E. Teunissen ^{2,9}, Frode S. Berven³ & Pieter Jelle Visser ^{1,2,15,16}

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this heterogeneity is critical for AD drug development. Here we define AD molecular subtypes using mass spectrometry proteomics in cerebrospinal fluid, based on 1,058 proteins, with different levels in individuals with AD ($n = 419$) compared to controls ($n = 187$). These AD subtypes had alterations in protein levels that were associated with distinct molecular processes: subtype 1 was characterized by proteins related to neuronal hyperplasticity; subtype 2 by innate immune activation; subtype 3 by RNA dysregulation; subtype 4 by choroid plexus dysfunction; and subtype 5 by blood–brain barrier impairment. Each subtype was related to specific AD genetic risk variants, for example, subtype 1 was enriched with *TREM2*R47H. Subtypes also differed in clinical outcomes, survival times and anatomical patterns of brain atrophy. These results indicate molecular heterogeneity in AD and highlight the need for personalized medicine.

Alzheimer's disease (AD) is the leading cause of dementia, affecting about 44 million people worldwide¹. AD is histopathologically defined by amyloid plaques and hyperphosphorylated tau tangles in the brain, but its underlying pathophysiology is largely unclear. Genetic, brain tissue proteomics and gene expression studies indicated that many different pathophysiological processes are associated with amyloid and tau pathology, including but not limited to synaptic plasticity, the innate immune system, neuroinflammation, lipid metabolism, RNA metabolism, the matrisome and vascular function^{2–8}. Differences between patients regarding the underlying mechanisms, together

with other factors, may have contributed to limited or lack of clinical effects observed in previous AD trials^{9–11}. For example, we previously found abnormally high cerebrospinal fluid (CSF) BACE1 levels in a specific AD subtype^{8,12}, suggesting that BACE inhibition may be effective in a subgroup only, provided that other factors are optimized. This highlights the need for personalized treatments and for in vivo tools to define such molecular subtypes.

CSF is the most accessible biofluid to study the molecular complexity of neurodegenerative diseases during life. It is in close contact with the brain and protein concentrations in the CSF reflect the brain's

ongoing (patho)physiological processes. We previously discovered and replicated three distinct molecular AD subtypes by investigating the 707 and 204 proteins in the CSF⁸. The proteins involved in these subtypes represent distinct biological processes, such as neuronal plasticity, innate immune activation and blood–brain barrier dysfunction⁸. Subtype-specific molecular alterations were already present at a very early stage of AD, when cognition was still intact and neuronal damage still limited. Many of these molecular processes were also previously identified in AD postmortem tissue proteomics or gene expression studies^{2,3,5,7}. This supports the value of CSF proteomics to detect AD pathophysiological processes in living patients³.

Proteomic techniques have greatly improved since and can detect thousands of proteins in the CSF, which provides an opportunity to dissect the molecular processes associated with AD subtypes in detail. In this study, we used these techniques and detected more than 3,000 proteins in the CSF in another independent cohort of 609 individuals to replicate and refine the existing subtypes, to test if the higher complexity allows us to uncover additional AD subtypes and to study the underlying genetic factors of these subtypes.

In our previous studies, we compared CSF AD subtypes on *APOE* e4 carrier status (the strongest genetic risk factor for sporadic AD)^{8,13} and on AD polygenic risk scores (PRS). In the current study, we further extended the genetic analyses and compared subtypes on AD risk variants from a recent genome-wide association study (GWAS)⁴. Moreover, we enriched for the relatively rare *TREM2* R47H and R62H mutations because these are associated with a 2.3 and 1.4-fold increased risk for AD⁴. *TREM2* R47H and R62H impair microglial activation in AD¹⁴. Therefore, we hypothesized that *TREM2* carriers could be grouped together in a subtype with impaired microglial activation. A small number of patients ($n = 6$) carried an autosomal dominant mutation in *PSEN1* or *APP*; we performed an exploratory analysis to identify which subtypes these genetic variants were associated with.

This large-scale CSF proteomic study revealed five molecular AD subtypes. Three subtypes recapitulated our previously identified three subtypes (hyperplasticity, innate immune activation and blood–brain barrier dysfunction)⁸. We further identified two additional AD subtypes: one with RNA dysregulation and one with choroid plexus dysfunction. All subtypes were associated with distinct genetic risk profiles, providing further biological validation for AD subtypes. The proteomic signatures associated with AD subtypes were present already at the preclinical stage and largely remained stable with increasing disease severity. Subtypes differed in the amount and pattern of cortical atrophy, cell type-specific expression of proteins, vascular damage and clinical outcomes. These results highlight the importance of neuronal plasticity, microglial impairment, innate immune activation, RNA processing, choroid plexus and blood–brain barrier dysfunction in AD pathogenesis, and provide a comprehensive resource that informs on the proteins and pathways that are dysregulated in patients with a specific AD subtype.

Results

We analyzed CSF samples from 609 individuals that were selected from the Alzheimer Center Amsterdam related studies^{15–18} (for clinical details, see Methods and Supplementary Table 1). Of this sample,

419 individuals had AD as defined by an abnormal amyloid biomarker and included all clinical stages (that is, 107 with normal cognition, 103 with mild cognitive impairment (MCI) and 209 with dementia). The 187 controls were required to have normal cognition and normal amyloid and tau biomarkers. CSF proteins from each sample were enzymatically digested and the peptides were labeled with tandem mass tags (TMTs), fractionated and analyzed by liquid chromatography–tandem mass spectrometry (LC–MS/MS) (Methods). A total of 3,863 proteins was identified, of which 1,309 proteins (defined by 28,408 peptides) were observed across all individuals. We then tested which proteins had different levels in individuals with AD compared to controls, and repeated those analyses stratified on tau levels or disease stage because protein levels can change in a nonlinear way with these variables^{12,19}. This led to the selection of 1,058 AD-related proteins for cluster analyses (Supplementary Table 2; it also includes information at the peptide level). We then clustered individuals with AD on AD-related proteins with nonnegative matrix factorization²⁰, which is a dual clustering approach (Supplementary Fig. 1). A particular strength of the algorithm is that individuals are per definition allocated to one subtype, which is useful for diagnosis or patient stratification for trials.

Five AD subtypes that differ on clinical characteristics

The patients' proteomic profiles clustered into five subtypes (Fig. 1a and Supplementary Table 3 for the fit and stability statistics): subtypes 1, 2 and 5 recapitulated our previously detected subtypes with neuronal hyperplasticity (subtype 1), innate immune activation (subtype 2) and blood–brain barrier dysfunction (subtype 5); two additional subtypes emerged: one with RNA dysregulation (subtype 3) and one with choroid plexus dysfunction (subtype 4). We tested the robustness of the subtypes by clustering the weighted protein coexpression network again with the Louvain algorithm (Methods), which also resulted in five protein clusters that were similar to the NMF protein clusters (93.5% overlap of cluster-specific proteins (Supplementary Table 4, column X). The next sections discuss each subtype in detail according to molecular, genetic and clinical characteristics. We briefly summarize the subtype differences. Subgroups were compared to controls and each other, with estimated marginal means from linear models for continuous outcomes, which were two-tailed tests, and proportions were tested with chi-squared tests and repeated for each pairwise group combination (Table 1, please note these comparisons are uncorrected for multiple testing because this is a descriptive table). Compared to controls, subtypes 1, 2 and 3 had increased CSF t-tau and p-tau levels, while subtypes 4 and 5 had mostly normal tau levels (see Table 1 and Supplementary Table 5 for additional analyses stratified according to cognitive state and adjusted for sex and age). Subtypes differed according to clinical stage, sex and age; all subsequent analyses took these characteristics into account. Compared to controls, subtypes differed in the rates of progression from MCI to dementia, with subtypes 2 and 5 having the highest risk, and subtype 4 the lowest (Fig. 2d), although differences between subtypes did not reach statistical significance (Supplementary Table 6a). Subtype 3 individuals with dementia had the shortest average survival time of 5.6 years, which was shorter than subtype 1 with the longest average survival time of 8.9 years ($P = 0.04$; Fig. 2 and

Fig. 1 | Biological description of AD subtypes. **a**, Patient subtypes projected to the uniform manifold approximation and projection (UMAP) space. **b**, CSF protein levels (rows) averaged across individuals within subtypes (columns). **c**, Cell-type-specificity signatures for proteins associated with the AD subtypes for proteins with increased (top row) and decreased (bottom row) level. The left circle diagram shows all cell types associated with a subtype combined. Proteins that could not be assigned to a specific cell type were not plotted (no colour to 100% in the left circle diagrams). The circle diagrams to the right zoom into the subcategories of specific cell types (neurons, glia, immune cells and endothelial cells). Cell-type specificity was determined according to the Human Protein Atlas. **d**, Top transcription factors associated with subtypes from the CHEA and

ENCODE databases. **e**, Gene Ontology (GO) biological pathways associated with subtypes (see Supplementary Table 9 for all pathways). **f**, AD genetic risk factors associated with specific subtypes; white indicates not statistically significant. Differences between subtypes and controls were determined from linear regression models with estimated marginal means, providing a two-tailed test for group comparisons, uncorrected for multiple testing because this is a post hoc comparison. Supplementary Tables 4 and 9–11 list all the proteins, pathways, and transcription and genetic factors tested with the statistical metrics. NS, not statistically significant; S1, subtype 1 (hyperplasticity); S2, subtype 2 (innate immune activation); S3, subtype 3 (RNA dysregulation); S4, subtype 4 (choroid plexus dysfunction); S5, subtype 5 (blood–brain barrier dysfunction).




Table 1 | Comparison of subtypes according to clinical characteristics

Characteristic	Controls n=187	Subtype 1 n=137	Subtype 2 n=124	Subtype 3 n=24	Subtype 4 n=78	Subtype 5 n=56
Cognitive state, n (%)						
Normal cognition	187 (100)	51 (37)	32 (26)	1 (4) ^{a,b}	15 (19) ^a	8 (14) ^a
MCI	0	37 (27)	28 (23)	3 (12)	16 (21)	19 (34)
Dementia	0	49 (36)	64 (52) ^a	20 (83) ^{a,b}	47 (60) ^a	29 (52) ^c
Age	64.01 (11.83)	64.71 (6.82)	69.38 (8.35) ^{a,d}	64.46 (8.73) ^b	64.28 (8.09) ^b	66.16 (8.11) ^b
Men, n (%)	111 (59)	62 (45) ^d	61 (49)	10 (42)	51 (65) ^{a,b}	41 (73%) ^{a,b,c}
Years of education, mean (s.d.)	12.4 (3.2)	12.1 (3.4)	11.2 (3.2) ^d	11.7 (2.9)	11.9 (3.4)	11.8 (3.3)
≥1 APOE e4 allele, n (%)	51 (28)	88 (68) ^d	73 (62) ^d	15 (65) ^d	47 (64) ^d	40 (74%) ^d
AD PRS, mean (s.d.)	5.6 (0.37)	5.8 (0.41) ^d	5.8 (0.31) ^d	6.0 (0.41) ^{d,b}	5.8 (0.46) ^d	5.8 (0.34) ^d
CSF total tau, pg ml ⁻¹ , mean (s.d.)	199 (88)	592 (340) ^d	765 (447) ^{a,d}	882 (367) ^{a,d}	301 (166) ^{a,b,c,d}	469 (297) ^{a,b,c,d,e}
CSF p-tau 181, z-score, mean (s.d.)	0 (0.99)	3.4 (2.5) ^d	5.1 (3.1) ^{a,d}	5.0 (2.5) ^{a,d}	0.6 (1.4) ^{a,b,c,d}	2.1 (2.3) ^{a,b,c,d,e}
CSF BACE1, pg ml ⁻¹ , mean (s.d.)	1931.9 (643.49)	2203.8 (479.07) ^d	2478.49 (687.98) ^{a,d}	2185.33 (573.92) ^{b,d}	1391.36 (323.74) ^{a,b,c,d}	1819.55 (560.55) ^{a,b,c,e}
CSF Abeta40, pg ml ⁻¹ , mean (s.d.)	7135.12 (2134.68)	7825.31 (1722.1) ^d	8519.82 (2264.92) ^{a,d}	6817.46 (1783.25) ^{a,b}	4610.78 (1286.96) ^{a,b,c,d}	5943.02 (1543.58) ^{a,b,c,d,e}
CSF NRG1, pg ml ⁻¹ , mean (s.d.)	317.49 (148.07)	488.01 (178.95) ^d	634.44 (300.5) ^{a,d}	561 (175.88) ^{b,d}	244.09 (97.64) ^{a,b,c,d}	370.91 (166.83) ^{a,b,c,e}
CSF NEFL, pg ml ⁻¹ , mean (s.d.)	360.1 (275.1)	447.01 (187.34) ^d	620.08 (341.41) ^{a,d}	630.12 (293.84) ^{a,d}	453.61 (292.84) ^{b,c,d}	594.16 (371.67) ^{a,d,e}
CSF VAMP2, pg ml ⁻¹ , mean (s.d.)	162.17 (70.43)	196.32 (61.39) ^d	233.44 (79.91) ^{a,d}	188.6 (61.77) ^b	100.1 (39.8) ^{a,b,c,d}	141.94 (52.35) ^{a,b,c,d,e}
Microbleed count on MRI, mean (s.d.)	0.91 (2.55)	1.89 (9.80)	1.16 (3.74)	1.65 (3.18)	2.07 (8.02)	4.40 (17.94) ^{b,d}

^aDiffers from subtype 1 with $P < 0.05$. ^bDiffers from subtype 2 with $P < 0.05$. ^cDiffers from subtype 3 with $P < 0.05$. ^dDiffers from controls with $P < 0.05$. ^eDiffers from subtype 4 with $P < 0.05$.

Supplementary Table 6b), and steeper decline on Mini Mental State Examination (MMSE), language and memory tests (Extended Data Figs. 1 and 2 and Supplementary Table 7). These results suggests that different underlying molecular processes may explain a part of between-patient variability in decline. Analysis of magnetic resonance imaging (MRI) scans in individuals with dementia ($n = 159$) indicated that subtypes differed in the degree and anatomical location of cortical atrophy (Fig. 2 and Supplementary Table 8). All subtypes had a higher prevalence of the APOE e4 genotype than controls, and a higher AD PRS, supporting their underlying AD genetic risk architecture. However, subtypes had distinct AD genetic risk profiles (discussed in detail below).

We next examined the molecular processes associated with the AD subtypes. For each subtype, we compared the levels of 2,878 proteins against the control group (Fig. 1b and Supplementary Table 4). Proteins with different levels between a subtype and the control group were included in the enrichment analyses to study associated biological processes and transcription factors. To aid comparability with the gene expression literature, we report gene names for proteins (see Supplementary Table 4 for the UniProt codes). Stratification according to clinical stage resulted in similar differences to controls (correlations of effects ranging between 0.85 and 0.98; Extended Data Fig. 4), further supporting that AD subtypes reflect specific disease traits^{8,13}.

Below, we highlight subtype-specific associations with biological processes, cell types, AD genetic risk variants and atrophy patterns (see Supplementary Tables 4–11 for detailed results).

Subtype 1 hyperplasticity

Subtype 1 individuals ($n = 137$, 32.7%) had 827 proteins with increased CSF levels and 408 proteins with decreased levels compared to

controls. Of all the subtypes, subtype 1 had the highest proportion of proteins specific for neurons, astrocytes, oligodendrocytes and oligodendrocyte precursor cells (Fig. 1c). Proteins with increased levels were associated with neuronal plasticity processes, including synapse assembly, axon guidance, neurogenesis and gliogenesis (Fig. 1e; see Supplementary Table 9 for all biological processes enriched). In addition, this neuronal hyperplasticity subtype had high BACE1, amyloid- β_{1-40} and tau CSF levels (Table 1), as we previously observed in the hyperplasticity subtype⁸. While high tau levels were previously thought to reflect neuronal loss due to tangle formation, more studies are indicating that this may also reflect other processes^{21,22}. For example, neurons with increased activity secrete more amyloid and tau^{23–27}; such hyperactive neurons have been observed near plaques²⁸. Fragments of amyloid and tau may in turn drive hyperplasticity through enhanced gene transcription²⁹. Indeed, proteins increased in subtype 1 were enriched for the transcription factors REST ($P_{\text{adjusted}} = 0.018 \times 10^{-13}$; Fig. 1d and Supplementary Table 7) and SUZ12 ($P_{\text{adjusted}} = 0.016 \times 10^{-12}$), which regulate plasticity-related processes through repression of neuronal differentiation genes^{30,31}. Previous studies pointed towards REST de-repression and increases of tau and plasticity-related processes in AD brain tissue^{7,32}, induced pluripotent stem cell (iPSC) neurons^{33,34} and tau tangle-bearing neurons³⁵. Comparing subtype 1 increased proteins with those studies, we found an overlap five of six from Lu et al.³², 65 of 173 from Meyer et al.³³ and 46 of 127 from Otero-Gracia³⁵ (Supplementary Table 4, columns AZ–BB). Moreover, with the higher number of proteins that we measured compared to our previous study, we found additional mechanisms that may contribute to the plasticity response observed in this subtype. For example, subtype 1 had the highest CSF levels of the lysosomal protein PLD3. High PLD3 levels have been reported in dystrophic neurites associated with amyloid




Fig. 2 | AD subtype comparisons on MRI and clinical outcomes. a, Median hippocampal volume as the percentage of total intracranial volume (TIV) compared to subtypes in the dementia stage. **b**, Choroid plexus volume as the percentage of TIV compared to subtypes in the dementia stage. **c**, Cortical atrophy associated with AD subtypes in the dementia stage compared to controls ($n = 160$). β indicates mean cortical thickness in mm, averaged over the right and left hemispheres and adjusted for age and sex. **d**, Clinical progression from MCI to dementia according to subtype (left; excluding subtype 3 due to $n = 2$) and

time from dementia to death according to subtypes (right). All atrophy measures are based on individuals with dementia only. **a, b**, The boxplots depict the median in the center; the boundaries indicate the first and third quartiles, while the whiskers extend up and down to 1.5 times the interquartile range (limited to actual observed data points), and the points indicate individual person values (subtype 1, $n = 37$; subtype 2, $n = 45$; subtype 3, $n = 12$; subtype 4, $n = 40$; subtype 5, $n = 25$). See Supplementary Tables 6a, b and 8 for the detailed statistical metrics.

axonal spheroids³⁶. Such spheroids trigger axonal remodeling and local hyperactivity³⁶. Dystrophic neurites also accumulate BACE1, which is associated with increased APP metabolism³⁷, and may explain the elevated BACE1 and amyloid- β levels in this subtype.

Next, we tested which AD genetic risk variants⁴ were overrepresented in this subtype compared to controls. We found enrichment for *TREM2*^{R47H} and variants in *LILRB2*, *RHOH* and *APP* (Fig. 1f and Supplementary Table 11a). This subtype also included three of the four *PSEN1* carriers and three of the four *NCK2* carriers (Supplementary Table 11b). *TREM2* is a transmembrane protein that can activate microglia when ligands, including amyloid fibrils, bind to its extracellular part¹⁴. The R47H variant alters the extracellular part, decreasing its ability to bind ligands, resulting in dampened microglial activation^{38,39}.

LILRB2 mediates *TREM2* signaling and has also been associated with dampened immune activation^{40,41}. *RHOH* and *NCK2* encode signaling molecules downstream from *TREM2* that influence cytoskeleton rearrangement of microglia, which enables migration toward pathogens and amyloid plaques⁴². Normally, activated microglia form a tight barrier around plaques, which decreases plaque surface and minimizes plaque contact with neurites^{14,38,43}. When microglial activation is dampened, as observed in carriers of *TREM2* variants, amyloid plaques are less compact, with toxic oligomers sticking out that could damage nearby neurites⁴⁴ and may lead to axonal dystrophy⁴⁴, possibly triggering a plasticity response as an attempt to repair. *TREM2* has also been implicated in impaired microglial synaptic pruning, which could further contribute to the hyperplasticity signature observed in

this subtype^{45–47}. Such an excess of synapses was previously associated with milder atrophy in *TREM2* mouse models⁴⁵. MRI analyses in our data indicated that this subtype had less atrophy compared to the other subtypes (Extended Data Fig. 3 and Supplementary Table 9), and was restricted to the temporal and parietal lobes.

Together, our results provide further support for a hyperplasticity subtype in AD, and provide additional insights into the underlying mechanisms, such as that this subtype could be related to a dampened microglial response. Therapies boosting *TREM2* activation are under development⁴⁸. We argue that individuals with this subtype may also respond to such treatments, even without carrying the *TREM2* R47H variant.

Subtype 2 innate immune activation

Subtype 2 individuals ($n = 124$, 29.6%) had, compared to controls, 986 proteins with increased CSF levels and 506 with decreased levels. A high proportion of proteins increased in subtype 2 was specific to microglia. Proteins with increased levels were associated with innate immune activation, including regulation of cytokine production. These included proteins from the complement complex (C1QA, C1QB, C1QC, C1S and C1R), as well as APOE and LPL, in line with our previous findings. Additionally, we now observed that this subtype also had increased levels of the microglial Tyro3, Axl and Mer (TAM) receptors AXL and MERTK, and GAS6 (a MERTK ligand), which can detect and engulf plaques⁴⁹. We further found increased PYCARD levels specifically in subtype 2. PYCARD is also known as apoptosis-associated speck-like protein containing a CARD (ASC), and is released by microglia with NLRP3 inflammasome activation^{50,51}. PYCARD can form ASC specks, which are fibrils that worsen amyloid aggregation⁵¹ and induce tau phosphorylation⁵², providing a potential mechanism through which microglial activation may aggravate AD pathology. Indeed, subtype 2 individuals had higher p-tau levels than seen in subtype 1 (Table 1). Other subtype 2 increased proteins were related to neuron-microglia signaling, including CSF1, CSF1R and CX3CL1. Neuroimmune signaling occurs during normal neuronal development when microglia prune immature synapses^{53–55}. In AD, activated microglia near diffuse and neuritic plaques may lead to excessive synaptic pruning⁵³. This could lead to exacerbated atrophy as shown in mouse models⁵⁶. In line with those models, subtype 2 was one of the two subtypes with the most severe and widespread cortical atrophy on MRI compared to subtypes 1, 3 and 5 (Extended Data Fig. 2). Still, despite this severe atrophy, the levels of proteins related to neuroplasticity were increased in this subtype and these proteins overlapped with subtype 1; they were also enriched for the transcription factors REST and SUZ12. Possibly, the increase of plasticity-related proteins may reflect an attempt to repair synaptic contacts, which succumbs in the presence of activated microglia. Alternatively, increased protein levels may reflect neuronal loss.

The AD genetic variants associated with this subtype were *IDUA*, *CLNK* and *SCIMP*, which are all involved in immune processes^{4,57}.

Together, these results give additional detailed insights into the innate immune activation AD subtype and suggest that an overactive innate immune system worsens the disease.

Subtype 3 RNA dysregulation

Subtype 3 ($n = 24$, 5.7%) emerged as one of the two additional subtypes. Compared to controls, this subtype had increased CSF levels for 516 proteins and decreased levels for 757 proteins. Proteins with increased levels were associated with cytoskeleton organization, axonal transport, and proteasome and protein folding (Supplementary Tables 4 and 9). This subtype had the highest t-tau and NEFL CSF levels. BACE1 levels were higher than in controls (Table 1), but unlike subtypes 1 and 2, amyloid- β_{40} levels were similar to controls, suggesting a different mechanism associated with higher BACE1 levels for this subtype. Proteins specifically increased in subtype 3 included heterogeneous nuclear ribonucleoproteins (hnRNPs) and other RNA-binding proteins, which

may point to RNA dysregulation. hnRNPs are involved in the maturation of pre-mRNAs, mRNA stabilization during transport and local mRNA translation for many RNAs, including those important for cytoskeleton organization⁵⁸. Disruptions in hnRNPs and mRNA have been associated with tau tangles in previous proteomic studies⁵⁹. Mislocalized hnRNPs could result in dysfunctional proteins due to mis-splicing or cryptic splicing⁶⁰. For example, TDP43 mislocalization can lead to cryptic splicing of *STMN2* (ref. 61), resulting in shorter proteins and decreased *STMN2* levels in tissue⁶². *STMN2* was detected in a subset ($n = 84$) of our sample, and subtype 3 had decreased levels of *STMN2* compared to controls. Transcription factors associated with subtype 3 increased proteins were KLF4 ($P_{\text{adjusted}} = 0.02 \times 10^{-15}$), which is associated with axon regeneration⁶³, and TAF1 ($P_{\text{adjusted}} = 0.008 \times 10^{-13}$) and MYC ($P_{\text{adjusted}} = 0.02 \times 10^{-10}$), which are interacting factors in cell differentiation processes^{64,65}. A previous gene expression study in brain tissue found a similar AD subtype with increased TAF1 and MYC signaling and aberrant synapse organization⁷.

When testing AD genetic risk factors, we found enrichment for *BINI*, which is known as 'Myc-box-dependent interaction protein'. One of *BINI*'s functions is to physically inhibit MYC⁶⁶. *BINI* mainly localizes in axons and has many isoforms arising from splicing⁶⁶. *BINI* mis-splicing has been associated with de-inhibition of MYC and cytoskeleton disruption⁶⁷. *TREM2* R62H was also associated with this subtype. Other genetic risk variants associated with subtype 3 included *SPDYE3*, involved in the cell cycle, *SNXI*, important for endosome sorting, and *KAT8*, a lysine acetyltransferase^{4,57}.

While RNA dysfunction has been mainly observed in frontotemporal dementia⁶⁸, these processes have also been observed in AD in tissue⁵ and tau tangle proteomic studies⁵⁹; our results suggests that this can be detected in the CSF of a specific AD subtype.

Subtype 4 choroid plexus dysfunction

Subtype 4 ($n = 78$, 18.6%) was the other additional subtype. Compared to controls, this subtype had increased CSF levels of 467 proteins and decreased levels of 626 proteins. A high proportion of proteins increased in subtype 4 were specific to microglia and other immune cells. Moreover, a large subset of proteins with increased levels (45%) was associated with high expression in the lateral ventricle choroid plexus (Supplementary Table 4), including TTR, SPARC and extracellular matrix proteins such as DCN, LUM and COLA12. Biological processes associated with subtype 4 included cell adhesion, and BMP and SMAD pathways, which are involved in choroid plexus development⁶⁹. The choroid plexus is located along the ventricles, where it produces CSF and is responsible for nutrient, lipid and protein transfer across the blood–CSF barrier⁶⁹. It consists of a highly developed extracellular matrix that connects a dense vasculature to its epithelial cells⁶⁹. On MRI, subtype 4 had the largest choroid plexus volume (Fig. 2b). Increased choroid plexus volume has been associated with inflammation and structural alterations in AD^{70,71}. Although this subtype most often had normal t-tau and p-tau levels (Table 1), it had worse atrophy than subtypes 1, 3 and 5, with specific involvement of anterior cingulate areas (Extended Data Fig. 3). Furthermore, proteins increased in subtype 4 were enriched for fibroblasts (Supplementary Table 4), which produce extracellular matrix proteins and provide structural support to the choroid plexus. Other proteins increased in subtype 4 included cytokines, such as CCL2, CCL21 and CCL15, which can attract monocytes and T lymphocytes⁷². Of note, proteins with decreased levels in subtype 4 were related to axonal outgrowth and synaptic plasticity (for example, BDNF), in part overlapping with proteins increased in subtypes 1 and 2, and were also enriched for REST and SUZ12. This suggests that subtype 2 is also characterized by neuronal hypoplasticity.

When testing AD genetic risk variants, we found enrichment for *ABCA7*, *PICALM*, *IL-34* and *CLNK*. While *ABCA7* and *IL-34* are expressed in the choroid plexus^{73,74}, *PICALM* is expressed in the blood–brain barrier⁷⁵. Both *ABCA7* and *PICALM* have a role in lipid metabolism^{76,77} and

have been associated with amyloid clearance in combination with LRP1 (ref. 78). *IL-34* has been associated with impaired macrophage function⁷⁹, which could interfere with the macrophage uptake of amyloid fibrils⁸⁰. Together with the decreased levels of BACE1 and amyloid- β_{40} in this subtype compared to controls (Table 1), suggesting decreased amyloid metabolism, these genetic factors suggests that impaired clearance mechanisms contribute to AD pathogenesis in subtype 4.

Taken together, these results suggest that choroid plexus dysfunction is another contributor to AD, in a specific subgroup of patients.

Subtype 5 blood–brain barrier dysfunction

Subtype 5 ($n = 56$, 13.4%) was highly similar to our previously identified blood–brain barrier dysfunction subtype with increased levels of 640 proteins that included blood proteins such as albumin, fibrinogens, plasminogen, prothrombin and many immunoglobulins, such as IgG1, all proteins that leak into the brain when the blood–brain barrier is compromised⁸¹. Pathways associated with increased proteins included blood coagulation, B cell-mediated immunity and acute inflammatory response. No transcription factor enrichment was observed for proteins with increased CSF levels. On MRI, this subtype had more microbleeds than controls ($P = 0.01$; Table 1), unlike the other subtypes. Most proteins associated with subtype 5 (1,013, 61%) had, however, decreased CSF levels compared to controls, and these were associated with neuroplasticity and converged on the transcription factors SUZ12 and REST. This suggests that the blood–brain barrier subtype also has hypoplasticity, like the choroid plexus subtype. Neuronal plasticity processes can be impaired by leakage of blood proteins, including fibrin, which were specifically increased in this subtype⁸². Furthermore, compared to our previous study, we found additional proteins altered in the blood–brain barrier subtype, which were associated with pericytes, cells that normally cover capillaries, and with particular vascular cell types, such as lower levels of PDGFRB, CDH2 (N-cadherin), MFGE8 (medin), HTRA1, LAMB1 (laminin), EDN1, LRP1 and JAM3, as well as increased levels of CDH5 (VE-cadherin), ANXA3, ICAM1, AMBP, VWF and PTPRB (Supplementary Table 4, columns AV–AX). All of these have been previously associated with deposition of blood proteins in the parenchyma^{75,83–87}. The low PDGFRb levels we observed may reflect loss of pericytes, which is in line with brain tissue measures of PDGFRb in rodent models and postmortem AD^{83,88}. A decreased number of pericytes might also explain the decreased levels of LRP1 we observed in this subtype, which may impede amyloid clearance across the blood–brain barrier⁷⁸. Alternatively, the low concentrations we observed in the blood–brain barrier subtype could reflect loss of other vascular cells, such as arterial smooth muscle cells, which also express PDGFRb⁸⁶.

In terms of genetic risk, this subtype had the highest proportion of *APOE* e4 carriers, although the difference with other subtypes did not reach statistical significance (Table 1). This subtype was further enriched for the *IL-34*, *ECHDC3* and *APP* variants. *IL-34* was also associated with the choroid plexus subtype, suggesting that it contributes to AD pathogenesis through processes related to the brain barrier. *ECHDC3* has been associated with lipid metabolism⁵⁷. Some variants in *APP* have been associated with vascular disruption or increased occurrence of cerebral amyloid angiopathy, through amyloid fragments that are more difficult to clear⁸⁹. The notion that this subtype has blood–brain barrier dysfunction, suggests that this common *APP* variant may contribute to AD risk through vascular integrity.

Together, these data provide additional insights into the underlying pathophysiological processes associated with the blood–brain barrier dysfunction AD subtype.

Predicting AD subtypes in replication cohorts

We then studied if the subtypes could be identified in six independent replication datasets with available CSF TMT MS. To this end, we trained random forest classifiers on the current dataset and then used these classifiers to predict subtype labels for individuals in the replication

cohorts, including patients from over nine different countries in Europe and the USA (Methods). All five subtypes were observed in most replication cohorts with high subtype-specific probabilities and comparable frequencies as in the discovery cohort: on average 27.9% had subtype 1, 35.5% subtype 2, 5.8% subtype 3, 17.1% subtype 4 and 16.6% subtype 5 (Fig. 3a and Supplementary Table 12). Subtype comparisons on CSF t-tau and p-tau levels, as well as age and sex, indicated mostly similar differences as observed in the main analyses for the replication cohorts (Fig. 3b–d and Supplementary Table 13). Replication cohort 4 also had CSF over the serum albumin ratios available (Fig. 3e), which is a marker for blood–brain barrier leakage; this was increased in the blood–brain barrier subtype only ($P < 0.0001$). Overall, these results suggests that the subtypes we discovered in the main analyses are also present in other cohorts.

Discussion


In this study, we dissected AD disease heterogeneity in patients with CSF proteomics, at a level of detail that approaches the level of complexity achieved in tissue proteomics^{2,6}. Our analyses included more proteins and individuals than in our previous study and this led to a more in-depth characterization of three previously identified CSF subtypes (that is, hyperplasticity, innate immune activation and blood–brain barrier dysfunction); two additional subtypes emerged, one with RNA dysregulation, which showed the most aggressive disease course, and one with choroid plexus dysfunction. Notably, we found that each subtype was associated with distinct AD genetic risk factors, further supporting that each CSF AD subtype reflects specific underlying molecular mechanisms. The subtypes also differed in cortical atrophy patterns and survival times, underscoring their clinical relevance.

A potential limitation of our study is that AD was defined with biomarkers, which correlate strongly with pathology but sometimes may be inaccurate. Another limitation is that we were unable to test if subtypes would have a different treatment response because we did not have access to samples from trials. Given the distinct patterns of molecular processes and AD genetic risk profiles, it is likely that AD subtypes will require specific treatments. For example, subtype 1 individuals may benefit from TREM2-activating treatments, subtype 2 from innate immune inhibitors, subtype 3 from antisense oligonucleotides that restore RNA processing, subtype 4 from inhibition of monocyte infiltration and subtype 5 from cerebrovascular treatments. At the same time, side effects arising from certain treatments may also depend on subtype. For example, while antibodies may more easily cross the blood–brain barrier in subtype 5, these individuals may be at increased risk for cerebral bleeding that can occur with antibody treatment. Future studies should aim to (re)analyze proteomics in clinical trial samples to test whether particular treatments have subtype-specific effects. To conclude, CSF-based subtyping may be useful to select individuals for a specific therapeutic treatment, either for a priori subject stratification or for responder and side effect analysis in clinical trials.

Methods

Participants

For this study, we selected individuals from studies performed at the Alzheimer Center Amsterdam under similar protocols (that is, Amsterdam Dementia Cohort (ADC)¹⁵, EMIF-AD preclinAD¹⁶ and 90+ studies¹⁷, and Amsterdam site participants who coenrolled in the ADC biobank and the EPAD study¹⁸) who provided written informed consent to use their data and biospecimens for research purposes. None of the individuals overlapped with our previous CSF proteomics study⁸. AD was defined based on the presence of an abnormal amyloid marker ($n = 419$), and controls were required to have normal cognition with normal amyloid markers (described in the ‘CSF ELISA measures’ section). Among the group with abnormal amyloid markers, 107 individuals had normal cognition, 103 had MCI and 209 had dementia according to international consensus criteria^{15–18}. When more individuals met



criteria for inclusion, preference was given to individuals with a known *TREM2* R47H ($n = 8$) or R62H mutation ($n = 28$; see the details in the 'Genetic data' section), to individuals without dementia with clinical follow-up ($n = 216$) and to individuals with available tau positron emission tomography (PET) ($n = 36$). Mortality information was obtained from the Dutch Municipal Register for ADC and EMIF-AD participants. All studies were approved by the ethics committee of the Amsterdam UMC (location VUmc), the Biobank Research Ethics Committee of the Amsterdam UMC (location VUmc) and the Ethics Committee of the University of Norway.

CSF collection and preparation for MS

CSF was collected by lumbar puncture between the L3/L4, L4/L5 or L5/S1 intervertebral space with a 25-gauge needle and syringe and collected in polypropylene tubes¹⁵. For all participants, CSF sample processing and biobank storage at the Alzheimer center biobank at the department of Laboratory Medicine was performed according to international guidelines¹⁵. The 610 samples were randomized over seven 96-well plates using random sampling as implemented in R to determine the layouts, 100 μ l CSF in each well and stored at -80°C . Researchers measuring the CSF samples were blinded to the diagnosis. Each sample plate was thawed on ice and 30 μ g protein (separate 96-well plates containing 40 μ l CSF were used to carry out the bicinchoninic acid (BCA) protein assay on 2×10 μ l CSF for the protein concentration measurements) from each well was transferred to 1.5 ml protein LoBind tubes and immediately frozen on dry ice. All samples were lyophilized using a freeze dryer and kept at -80°C before digestion. Urea protein digestion was performed as follows. Each day until there were no more samples to process, 28 samples together with one quality control sample and two reference samples were added (20 μ l of 8 M urea/20 mM methylamine), vortexed for 5 min at 1,000 r.p.m. and sonicated for 30 s in ice-cold water. The urea solution was diluted with 20 μ l of 50 mM Tris HCl/1 mM CaCl_2 , pH 7.6, followed by cysteine reduction (0.4 μ mol dithiothreitol (DTT), 1 h incubation at room temperature) and alkylation (1 μ mol iodoacetamide, 1 h incubation in the dark at room temperature). To avoid protease alkylation, excess iodoacetamide was allowed to react with DTT by adding 0.08 μ mol of the reagent before diluting the urea to 1 M with 50 mM Tris HCl/1 mM CaCl_2 , pH 7.6. Trypsin digestion was performed for 16 h at 37°C after adding 0.6 mg of the protease (porcine trypsin, Promega Corporation). Sample cleanup was performed using a reverse-phase Oasis 96-well HLB μ Elution Plate 30 μ m (2 mg HLB sorbent, Waters). After lyophilization, the quality control samples were resuspended in 25 μ l 2% acetonitrile (ACN)/0.5% formic acid. All other samples were resuspended in 20 μ l of 50 mM HEPES buffer, pH 8.2, 4-(2-hydroxyethyl) 2-piperazin-1-ylethanesulfonic acid) before TMT labeling. Samples were vortexed for 30 s at 1,500 r.p.m. and sonicated for 30 s in an ultrasonic bath. Each reporter in a 5-mg TMTpro 16plex reagent set was dissolved in 1 ml anhydrous ACN. The 610 samples were labeled in 44 experiments, where each experiment contained 14 samples and 2 reference samples. For each sample, the 20- μ l label was added. The labeling reaction was stopped by adding 5 μ l 5% hydroxylamine after 75 min. The 16 labeled samples for each experiment were combined and lyophilized (about 240 μ g protein); approximately 150 μ g were desalted using a reverse-phase Oasis 96-well HLB Elution Plate 30 μ m (10 mg HLB sorbent, Waters). After lyophilization, the 44 samples were dissolved in 150 μ l of 10 mM ammonium formate, pH 7.9; 65 μ l were fractionated using an off-line high-performance liquid chromatography (HPLC) system (Agilent 1260 infinity, Agilent Technologies) equipped with a reverse-phase column (XSelect CSH C18, 130 \AA , 3.5 μ m, 1×150 mm, Waters). Using high-pH reverse-phase chromatography, peptides were separated during a biphasic ACN gradient from two HPLC pumps (flow rate of 50 μ l min^{-1}). Solvents A and B were 10 mM ammonium formate, pH 7.9, in water and 90% ACN/10% water, respectively. The gradient composition was 5% B during trapping (2 min) followed by 5–12% B over 1 min, 12–44% B

for the next 35 min, 44–70% B over 10 min and 70–95% B over 2 min. Elution of very hydrophobic peptides and conditioning of the column were performed for a 5-min isocratic elution with 95% B and a 12-min isocratic elution with 5% B, respectively. Peptides were collected in a 500- μ l protein LoBind 96-well plate during peptide elution; ten fractions were collected. The first fraction was collected in two wells from 5 to 16 min (5.5 min per well, merged into one fraction); the next eight fractions (2.7 min per fraction) were collected between 16 and 37.6 min; the last fraction was collected in two wells between 37.6 and 53.6 min (8 min per well, merged into one fraction). Fractions were lyophilized and resuspended in 10 μ l 2% ACN/0.5% formic acid, and peptide concentrations were measured with a NanoDrop UV-Vis spectrophotometer (Thermo Fisher Scientific) before LC-MS/MS analysis.

LC-MS/MS

About 0.5 μ g tryptic TMT-labeled peptides were injected into an Ultimate 3000 RSLC system (Thermo Fisher Scientific) connected online to a Exploris 480 mass spectrometer (Thermo Fisher Scientific) equipped with an EASY-Spray nano-electrospray ion source. Peptides were desalted on a precolumn (Acclaim PepMap 100, 2 cm \times 75 μ m ID nanoViper column, packed with 3 μ m C18 beads) at a flow rate of 5 μ l min^{-1} for 5 min with 0.1% trifluoroacetic acid before separation on a 50-cm analytical column (PepMap RSLC, 50 cm \times 75 μ m ID EASY-Spray column, packed with 2 μ m C18 beads). During a biphasic ACN gradient from two nanoflow UPLC pumps (solvent A and B were 0.1% formic acid (vol/vol) in water and 100% ACN, respectively), peptides were separated through the reverse-phase column at a flow rate of 200 nl min^{-1} . The gradient composition was 5% B during trapping (5 min) followed by 5–8% B over 1 min, 8–30% B for the next 104 min, 30–40% B over 15 min and 40–80% B over 3 min. Elution of very hydrophobic peptides and conditioning of the column was performed for a 9-min isocratic elution with 80% B and a 10-min isocratic elution with 5% B. The LC was controlled through an SII for Xcalibur 1.6 (Thermo Fisher Scientific).

Peptides eluted from the column were detected in the Exploris 480 mass spectrometer (capillary temperature at 275°C and ion spray voltage at 2100 V) with high-field asymmetric waveform ion mobility spectrometry (FAIMS) enabled using two compensation voltages (CVs) (-50V and -70V), and 'advanced peak determination' on. During each CV, the mass spectrometer was operated in the data-dependent acquisition (DDA) mode to automatically switch between one full scan MS and MS/MS acquisition. Instrument control was through an Orbitrap Exploris 480 Tune 3.1 and Xcalibur 4.4. The cycle time was maintained at 1.5 s per CV. The FAIMS filter performed gas-phase fractionation, enabling the preferred accumulation of multiply charged ions to maximize the efficiency of the DDA. FAIMS results in less precursor coisolation and cleaner MS/MS spectra. MS spectra were acquired in the scan range of 375–1,500 m/z with resolution $R = 60,000$ at 200 m/z , automatic gain control target of 3×10^6 and a maximum injection time at auto (depending on the transient length in the Orbitrap). The most intense eluting peptides with charge states 2–6 and above an intensity threshold of 2×10^4 were sequentially isolated to a standard target value of 2×10^5 , or a maximum injection time of 120 ms in the C-trap, and isolation width maintained at 0.7 m/z (quadrupole isolation), before fragmentation in the higher-energy collision dissociation. Fragmentation was performed with a normalized collision energy of 32%; fragments were detected in the Orbitrap at a resolution of 45,000 at 200 m/z , with first mass fixed at 110 m/z . One MS/MS spectrum of a precursor mass was allowed before dynamic exclusion for 45 s with 'exclude isotopes' on. Lock-mass internal calibration was not enabled.

The resulting .raw files were processed using Proteome Discoverer 2.5. The database file used for the search using Sequest HT was Swiss-Prot with 20,395 entries (v.20210413.fasta). The following modifications were made in the database search: precursor mass tolerance: 10 ppm; fragment mass tolerance: 0.02 Da; static peptide N terminus: TMTpro/ + 304.207 Da (any N terminus); static modification:

TMTpro/ + 304.207 Da (K); static modification: carbamidomethyl (C); and dynamic modification for methionine oxidation. The maximum of missed cleavage sites was set to 2, with a minimum peptide length of 6. The validation settings were set to 0.01 for strict PSM false discovery rate (FDR) using a target-decoy strategy and 0.05 for relaxed. The peptides used were set to unique + razor. Reporter abundance was based on intensity with a coisolation threshold of 50 and average reporter S/N threshold of ten. The output files were then gathered and subjected to further processing.

CSF enzyme-linked immunosorbent assay

Amyloid- β_{42} , t-tau and p-tau were previously determined using an enzyme-linked immunosorbent assay (ELISA) from Innostest (Fujirebio, formerly Innogenetics) in the ADC, or with the Roche Elecsys System ($n = 15$ from ADC and in EPAD). In the EMIF-AD preclinAD study, amyloid status was determined based on the amyloid- β_{42} /amyloid- β_{40} ratio, which, together with t-tau and p-tau 181, were measured with ELISAs from ADx NeuroSciences/EUROIMMUN. In the EMIF-AD 90+, amyloid status was determined with visual reading of flutemetamol (^{18}F) PET. For these individuals ($n = 22$), tau levels were computed from the TMT microtubule-associated protein tau (MAPT) measures, which correlated strongly ($r = 0.81$, $P < 0.001$) with the Innostest t-tau levels in the ADC cohort (formula: Inno t-tau = $-309.16 + 0.01 \times \text{MAPT}$). For tau categorization, we used t-tau values because these were available for all individuals and correlated strongly with p-tau levels ($r = 0.94$, $P < 0.001$). We used published cutoffs to label individuals as having a normal AD CSF profile or abnormal amyloid based on CSF^{90–94}. Three individuals with normal cognition had normal amyloid and abnormal CSF t-tau levels, which were excluded from the present analyses, resulting in a final sample size of 187 controls and 419 individuals with abnormal amyloid. We standardized continuous amyloid 1–42, t-tau and p-tau 181 values within specific assays according to the mean and s.d. of controls to compare these values between subtypes. Finally, we measured BACE1, amyloid- β_{40} and neurogranin with EUROIMMUN ELISA assays (Germany), NEFL with ADx NeuroSciences (Belgium) ELISA assay and VAMP2 with a prototype assay developed by ADx NeuroSciences (Belgium) with single-molecule array technology (Quanterix Corporation) as described previously⁹⁵. These measures were not included in clustering, but used as independent markers to compare AD subtypes.

Genetic data

APOE genotyping was performed in blood. A subset of 560 individuals had genotyping data available (Illumina Global Screening Array). Details on quality control procedures were described previously⁹⁶; for EPAD, they are available on GitHub at <https://github.com/marioningroup/epad-gwas>. Genotype VCF files were imputed using the TopMed reference panel. Eighty-three genetic risk loci for AD were selected based on their previous genome-wide association with AD⁴. These single-nucleotide polymorphisms (SNPs) were extracted from the genetic data based on rsID or base pair location in the genome. Protective SNPs (that is, odds ratios < 1) were inverted, such that for all SNPs higher values indicate higher AD risk.

MRI data

A subset 503 individuals had structural T1-weighted MRI available. To test if subtypes were characterized by different atrophy patterns, we restricted analyses to subtypes in the dementia stage ($n = 159$ and 160 controls) because in that stage atrophy is most pronounced. Acquisition details were described previously^{16,97–99}. Cortical thickness, hippocampal volume, choroid plexus volume and total intracranial volumes were estimated with FreeSurfer v.7.1.1 (<http://surfer.nmr.mgh.harvard.edu/>). Cortical thickness and volumetric estimates were summarized in anatomical regions as defined by the FreeSurfer implementation of the Desikan–Killiany atlas. Choroid plexus and hippocampal volumes were adjusted for total intracranial volume to adjust interindividual

differences in head size. Furthermore, microbleeds were counted on T2* sequences by an experienced neuroradiologist and defined as small round hypointense foci up to 10 mm in the brain parenchyma.

Longitudinal cognitive assessment

Most individuals had clinical follow-up available that was planned approximately on a yearly basis. Follow-up diagnoses were based on the same criteria as described above for the baseline diagnosis. Cognitive functioning was assessed globally with the MMSE and for specific cognitive domains with standardized neuropsychological test batteries at the first visit and repeated over time^{15–18}. We selected tests that were comparable across substudies: for memory, the immediate and delayed recall of the Dutch version of the Rey auditory verbal learning tasks (ADC and EMIF-AD preclinAD), the Consortium to Establish a Registry for Alzheimer's Disease 10-word test (EMIF-AD 90+) or the RBANS 10-word list learning (EPAD); for language, the 1-min animal fluency test (ADC, EMIF-AD preclinAD and 90+) and the Repeatable Battery for the Assessment of Neuropsychological Status 1-min category fluency (EPAD); for attention, the TMT-A test (ADC, EMIF-AD preclinAD and 90+ only); and for executive functioning, the TMT-B test (ADC, EMIF-AD preclinAD and 90+ only). The TMT-A and TMT-B scores were inverted so that, like the other tests, lower scores indicate worse performance. All neuropsychological test scores were standardized according to the mean and s.d. of the baseline scores of the control group in each substudy separately. Baseline animal fluency scores were missing for EMIF-AD preclinAD individuals, which were imputed before standardizing.

Statistics and reproducibility

Sample size for the present analyses was determined before this study, using a simulation study based on our previous results, which included 284 individuals with three subtypes⁸. Simulating a protein correlation structure with 4–6 additional subtypes required 300–400 participants. Therefore, we selected 419 individuals with AD and 187 controls. The researchers measuring the proteomics in CSF were blinded to the diagnosis. The researchers performing the statistical analyses were not blinded to the diagnosis because the diagnosis was required for the subgroup analyses. All samples were randomized over the TMT experiments using random sampling as implemented in R to determine the layouts. One person for whom proteomics was measured (selected based on the presence of tau PET) was excluded from further analyses in this study because they had normal AD markers in CSF but a clinical diagnosis of primary progressive aphasia, leaving 609 individuals included for the statistical analyses. Because we performed data-driven analyses to study clusters in the data, no randomization method was used to allocate individuals to the experimental groups. Technical deviations may have influenced protein abundance across the TMT experiments. Before the statistical analyses, we normalized protein abundance according to the internal reference scaling normalization procedure¹⁰⁰ for TMT proteomics data that use the common pool reference channels to normalize values between plex experiments, adapted to scale according to the median instead of the total sum to reduce the influence of outliers. Briefly, the first step in this two-step approach normalized the grand total protein intensities for each of the 14 channels within an experiment to match these to the two reference channels. In the second step, a correction factor was calculated based on common pooled internal standards to normalize reporter ion intensities of proteins between TMT experiments. Internal standards were unavailable for 113 proteins, which were excluded from the subsequent analyses. Extended Data Fig. 5 illustrates that batch effects were removed. Next, protein values were \log_2 -transformed and then scaled according to the mean and s.d. of the control group, so that positive and negative values indicate higher and lower than normal. For all proteins, we report gene names to aid comparisons with other AD subtyping literature using either proteomics or RNA-seq data.

AD subtype discovery

Our objective was to identify subtypes within AD, and so we first selected proteins that were related to AD. For this, we compared all AD individuals to controls with regard to the CSF levels of proteins that were observed in the complete sample with Kruskal–Wallis tests. Because previous studies indicated that AD-related alterations of CSF protein levels may depend on cognitive state or tau status in a nonlinear way¹², we repeated these analyses stratified for these factors. This resulted in 1,058 proteins that were selected for clustering with nonnegative matrix factorization as implemented in the NMF package v.0.25 in R v.4.2.2. Bird Hippie. We followed the procedure as in our previous study³. Briefly, proteins were first scaled to have positive values between 1 and 2, keeping the relative values intact. Next, we performed 30 different runs of NMF to determine the number of clusters (that is, the subtypes) that best described the data. We tested up to ten clusters, and found that five clusters showed an optimal balance of a high cophonetic coefficient, at least twofold improved fit over the lower clustering solution, compared to improvement using a random cluster solution, and a silhouette score greater than 0.5 (Supplementary Table 3). To test the robustness of clusters, we repeated clustering using the Louvain algorithm on the protein coexpression networks, excluding the diagonal and setting the resolution parameter to 1.15, as implemented in the *igraph* R package v.1.3.2. Next, we labeled each individual patient according to the subtype that best matched their proteomics profile. Patient-level subtype clusters were visualized by projecting the NMF subtype scores to a UMAP embedding, via construction of a *k*-nearest neighbor graph using the *uwot* R package v.0.1.14. Patient-level subtype labels provide the basis for all subsequent post hoc comparisons described in the next sections.

Biological characterization of AD subtypes

We characterized the biological processes associated with AD subtypes by comparing the subtypes on CSF protein levels of all available proteins, including, in addition to the fully observed proteins, also proteins with missing values when they had at least five observations available in each subtype group (2,907 proteins in total). For this we used linear models with participant subtype status as predictors and protein levels as outcomes. We repeated the analyses correcting for age and sex, and stratifying according to cognitive state to determine the influence of these factors on the results. All subtypes were compared to the control group, as well as to each other; results from all comparisons are reported in Supplementary Table 4. We performed pathway enrichment analyses for biological processes from the GO 13 January 2022 release as accessed using Panther v.16.0, for the proteins that were associated with each subtype (that is, differed from the controls with $P < 0.05$), separately for increased and decreased alterations. A hypergeometric Fisher exact test was used for pathway enrichment and pathway *P* values were corrected for multiple testing with the FDR procedure. We further tested if AD subtype-related proteins were associated with potential upstream transcription factors from the CHEA and ENCODE databases through ENRICH. We further annotated proteins according to cell type specificity using the Human Protein Atlas (<https://www.proteinatlas.org>) and the RNA-seq Barres database¹⁰¹; for specific vascular cell types with Garcia et al.⁸⁶ and Yang et al.⁷⁵; for choroid plexus associations according to the harmonizome database¹⁰²; for REST signaling associations based on Meyer et al.³³ and Otero-Garcia et al.¹⁰³; for blood–brain barrier dysfunction according to Dayon et al.⁸¹; and for the CSF pathway panels informed by tissue proteomics to Higginbotham et al.³

Post hoc comparisons between subtypes on clinical characteristics

We performed post hoc tests to characterize AD subtypes clinically and biologically with chi-squared tests² for discrete variables (sex and APOE e4 genotype), and with linear regression models for continuous

variables correcting for age and sex when applicable. Subtype differences with regard to time to progress to dementia was tested with Cox proportional-hazards models and restricted to the prodromal stage of individuals for reasons of statistical power. Subtype differences in survival times were also tested with Cox proportional-hazards models, and restricted to individuals in the dementia stage for reasons of statistical power. Subtype differences on baseline cognitive test scores, as well as changes over time, were tested with linear mixed models, stratified according to disease stage. Subtype differences with controls on genetic variants as continuous outcomes were tested with linear regression models, taking imputation uncertainty into account when possible. Missing values (*n*) were recorded for years of education (*n* = 6), APOE genotype (*n* = 26), AD PRS (*n* = 68), CSF p-tau (*n* = 26), CSF NEFL (*n* = 3) and microbleeds on MRI (*n* = 163). All analyses were repeated with age and sex as covariates (and level of education for cognitive data).

Predicting AD subtypes in replication cohorts

We trained random forest classifiers in the discovery cohort to predict AD subtypes in the replication cohorts that had proteomics data available with TMT MS in CSF in individuals with AD and controls. Procedures for the replication cohort 1 were previously described by Tijms et al.⁸, replication cohort 2 by Modeste et al.¹⁰⁴, replication cohort 3 by Dammer et al.¹⁰⁵ and Higginbotham et al.³, replication cohort 4 by Dayon et al.¹⁰⁶ (provided with ref. 3), and replication cohorts 5 and 6 by Johnson et al.¹⁰⁷. First, for each cohort we normalized between plex experiments in the same way in the discovery cohort. Next, we scaled proteins according to the mean and s.d. of the control group (that is, normal cognition and normal CSF amyloid and tau markers). We then determined for each cohort which proteins were observed in all samples and matched these proteins to the discovery cohort based on UniProt codes. The replication cohorts differ in the proteins detected; so we trained four random forest classifiers to include as much overlapping proteins as possible across cohorts, starting with the cohort with the most overlap with the current study (that is, replication cohorts 1 and 2; see columns Y-AB in Supplementary Table 4 for the proteins included). Each random forest was trained on 80% of the discovery data and tested on the left out 20% using random sampling without replacement. For each training set, subtype frequencies were balanced across classes with SCUT (*scutr* R package v.0.1.2), which uses the SMOTE algorithm to simulate additional cases in minority classes, and *k*-nearest neighbor clusters to undersample the majority classes. The same training and test data were used for each of the four types of random forests to compare prediction accuracies between forests. We repeated the training and testing procedure for all random forests 100 times to determine classification stability. Random forests were trained with *ntree* set to 1,000 and then used for prediction with the *randomForest* R package v.4.7-1.1. In each replication set, we assigned individuals to the subtype with the highest predicted probability. Next, we tested if subtypes had comparable differences on CSF t-tau and p-tau levels as the discovery cohort; for replication cohort 4, subtypes were also compared on the CSF serum albumin ratio as an index of blood–brain barrier dysfunction. Note that these measures were not included in the random forests. Finally, subtypes were compared according to APOE genotype, sex and age.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All mass spectrometry data generated for this study with accompanying demographical information are available through the ADDI workbench (https://fair.addi.ad-datainitiative.org/#/data/datasets/five_csf_proteomic_subtypes_in_ad; <https://doi.org/10.58085/HR6S-2991>).

Other data used in this publication were accessed as described in the Methods. All other data are available from the corresponding author upon reasonable request.

References

- Nichols, E. et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health* **7**, e105–e125 (2022).
- Johnson, E. C. B. et al. Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level. *Nat. Neurosci.* **25**, 213–225 (2022).
- Higginbotham, L. et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. *Sci. Adv.* **6**, eaaz9360 (2020).
- Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat. Genet.* **54**, 412–436 (2022).
- Neff, R. A. et al. Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals novel mechanisms and targets. *Sci. Adv.* **7**, eabb5398 (2021).
- Hondius, D. C. et al. Profiling the human hippocampal proteome at all pathologic stages of Alzheimer's disease. *Alzheimers Dement.* **12**, 654–668 (2016).
- Caldwell, A. B. et al. Transcriptomic profiling of sporadic Alzheimer's disease patients. *Mol. Brain* **15**, 83 (2022).
- Tijms, B. M. et al. Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. *Brain* **143**, 3776–3792 (2020).
- Haerberlein, S. B. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. *J. Prev. Alzheimers Dis.* **9**, 197–210 (2022).
- van Dyck, C. H. et al. Lecanemab in early Alzheimer's disease. *N. Engl. J. Med.* **388**, 9–21 (2022).
- Egan, M. F. et al. Randomized trial of verubecestat for prodromal Alzheimer's disease. *N. Engl. J. Med.* **380**, 1408–1420 (2019).
- Visser, P. J. et al. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. *Mol. Neurodegener.* **17**, 27 (2022).
- Tijms, B. M. et al. CSF proteomic Alzheimer's disease-predictive subtypes in cognitively intact amyloid negative individuals. *Proteomes* **9**, 36 (2021).
- Ulrich, J. D., Ulland, T. K., Colonna, M. & Holtzman, D. M. Elucidating the role of TREM2 in Alzheimer's disease. *Neuron* **94**, 237–248 (2017).
- van der Flier, W. M. et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. *J. Alzheimers Dis.* **41**, 313–327 (2014).
- Konijnenberg, E. et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. *Alzheimers Res. Ther.* **10**, 85 (2018).
- Legdeur, N. et al. Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. *BMC Geriatr.* **18**, 289 (2018).
- Ritchie, C. W. et al. The European Prevention of Alzheimer's Dementia (EPAD) longitudinal cohort study: baseline data release V500.0. *J. Prev. Alzheimers Dis.* **7**, 8–13 (2020).
- de Leon, M. J. et al. The nonlinear relationship between cerebrospinal fluid A β_{42} and tau in preclinical Alzheimer's disease. *PLoS ONE* **13**, e0191240 (2018).
- Lee, D. D. & Seung, H. S. Learning the parts of objects by non-negative matrix factorization. *Nature* **401**, 788–791 (1999).
- Karch, C. M., Jeng, A. T. & Goate, A. M. Extracellular tau levels are influenced by variability in tau that is associated with tauopathies. *J. Biol. Chem.* **287**, 42751–42762 (2012).
- Sato, C. et al. Tau kinetics in neurons and the human central nervous system. *Neuron* **97**, 1284–1298 (2018).
- Pooler, A. M., Phillips, E. C., Lau, D. H. W., Noble, W. & Hanger, D. P. Physiological release of endogenous tau is stimulated by neuronal activity. *EMBO Rep.* **14**, 389–394 (2013).
- Yamada, K. et al. Neuronal activity regulates extracellular tau in vivo. *J. Exp. Med.* **211**, 387–393 (2014).
- Kaesler, S. A. et al. CSF p-tau increase in response to A β -type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles. *Acta Neuropathol.* **143**, 287–290 (2022).
- Cirrito, J. R. et al. Synaptic activity regulates interstitial fluid amyloid- β levels in vivo. *Neuron* **48**, 913–922 (2005).
- Kamenetz, F. et al. APP processing and synaptic function. *Neuron* **37**, 925–937 (2003).
- Busche, M. A. et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. *Science* **321**, 1686–1689 (2008).
- Zott, B. et al. A vicious cycle of β amyloid-dependent neuronal hyperactivation. *Science* **365**, 559–565 (2019).
- Tsai, M.-C. et al. Long noncoding RNA as modular scaffold of histone modification complexes. *Science* **329**, 689–693 (2010).
- Ballas, N. & Mandel, G. The many faces of REST oversee epigenetic programming of neuronal genes. *Curr. Opin. Neurobiol.* **15**, 500–506 (2005).
- Lu, T. et al. REST and stress resistance in ageing and Alzheimer's disease. *Nature* **507**, 448–454 (2014).
- Meyer, K. et al. REST and neural gene network dysregulation in iPSC models of Alzheimer's disease. *Cell Rep.* **26**, 1112–1127 (2019).
- Caldwell, A. B. et al. Dedifferentiation and neuronal repression define familial Alzheimer's disease. *Sci. Adv.* **6**, eaba5933 (2020).
- Otero-Garcia, M. et al. Single-soma transcriptomics of tangle-bearing neurons in Alzheimer's disease reveals the signatures of tau-associated synaptic dysfunction. *Neuron* **110**, 2929–2948 (2022).
- Yuan, P. et al. LD3 affects axonal spheroids and network defects in Alzheimer's disease. *Nature* **612**, 328–337 (2022).
- Sadleir, K. R. et al. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A β generation in Alzheimer's disease. *Acta Neuropathol.* **132**, 235–256 (2016).
- McQuade, A. et al. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer's disease. *Nat. Commun.* **11**, 5370 (2020).
- Cosker, K. et al. Microglial signalling pathway deficits associated with the patient derived R47H TREM2 variants linked to AD indicate inability to activate inflammasome. *Sci. Rep.* **11**, 13316 (2021).
- Zhao, P. et al. LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. *Mol. Neurodegener.* **17**, 44 (2022).
- De Strooper, B. & Karran, E. The cellular phase of Alzheimer's disease. *Cell* **164**, 603–615 (2016).
- Romero-Molina, C., Garretti, F., Andrews, S. J., Marcora, E. & Goate, A. M. Microglial efferocytosis: diving into the Alzheimer's disease gene pool. *Neuron* **110**, 3513–3533 (2022).
- Zhao, R., Hu, W., Tsai, J., Li, W. & Gan, W.-B. Microglia limit the expansion of β -amyloid plaques in a mouse model of Alzheimer's disease. *Mol. Neurodegener.* **12**, 47 (2017).
- Yuan, P. et al. TREM2 haploinsufficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. *Neuron* **90**, 724–739 (2016).
- Gratuzze, M. et al. Impact of TREM2^{R47H} variant on tau pathology-induced gliosis and neurodegeneration. *J. Clin. Invest.* **130**, 4954–4968 (2020).

46. Filipello, F. et al. The microglial innate immune receptor TREM2 is required for synapse elimination and normal brain connectivity. *Immunity* **48**, 979–991 (2018).
47. Stoiljkovic, M., Gutierrez, K. O., Kelley, C., Horvath, T. L. & Hajós, M. TREM2 deficiency disrupts network oscillations leading to epileptic activity and aggravates amyloid- β -related hippocampal pathophysiology in mice. *J. Alzheimers Dis.* **88**, 837–847 (2022).
48. van Lengerich, B. et al. A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models. *Nat. Neurosci.* **26**, 416–429 (2023).
49. Huang, Y. et al. Microglia use TAM receptors to detect and engulf amyloid β plaques. *Nat. Immunol.* **22**, 586–594 (2021).
50. Heneka, M. T. et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. *Nature* **493**, 674–678 (2013).
51. Venegas, C. et al. Microglia-derived ASC specks cross-seed amyloid- β in Alzheimer’s disease. *Nature* **552**, 355–361 (2017).
52. Ising, C. et al. NLRP3 inflammasome activation drives tau pathology. *Nature* **575**, 669–673 (2019).
53. Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science* **352**, 712–716 (2016).
54. Paolicelli, R. C. et al. Synaptic pruning by microglia is necessary for normal brain development. *Science* **333**, 1456–1458 (2011).
55. Hu, B. et al. Insights into the role of CSF1R in the central nervous system and neurological disorders. *Front. Aging Neurosci.* **13**, 789834 (2021).
56. Maphis, N. et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. *Brain* **138**, 1738–1755 (2015).
57. Tábuas-Pereira, M., Santana, I., Guerreiro, R. & Brás, J. Alzheimer’s disease genetics: review of novel loci associated with disease. *Curr. Genet. Med. Rep.* **8**, 1–16 (2020).
58. Geuens, T., Bouhy, D. & Timmerman, V. The hnRNP family: insights into their role in health and disease. *Hum. Genet.* **135**, 851–867 (2016).
59. Kavanagh, T., Halder, A. & Drummond, E. Tau interactome and RNA binding proteins in neurodegenerative diseases. *Mol. Neurodegener.* **17**, 66 (2022).
60. Sidhu, R., Gatt, A., Fratta, P., Lashley, T. & Bampton, A. HnRNP K mislocalisation in neurons of the dentate nucleus is a novel neuropathological feature of neurodegenerative disease and ageing. *Neuropath. Appl. Neurobiol.* **48**, e12793 (2022).
61. Melamed, Z. et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. *Nat. Neurosci.* **22**, 180–190 (2019).
62. Yu, Q.-S., Feng, W.-Q., Shi, L.-L., Niu, R.-Z. & Liu, J. Integrated analysis of cortex single-cell transcriptome and serum proteome reveals the novel biomarkers in Alzheimer’s disease. *Brain Sci.* **12**, 1022 (2022).
63. Moore, D. L. et al. KLF family members regulate intrinsic axon regeneration ability. *Science* **326**, 298–301 (2009).
64. Wei, Y. et al. Multiple direct interactions of TBP with the MYC oncoprotein. *Nat. Struct. Mol. Biol.* **26**, 1035–1043 (2019).
65. Majd, S., Power, J. & Majd, Z. Alzheimer’s disease and cancer: when two monsters cannot be together. *Front. Neurosci.* **13**, 155 (2019).
66. Tan, M.-S., Yu, J.-T. & Tan, L. Bridging integrator 1 (BIN1): form, function, and Alzheimer’s disease. *Trends Mol. Med.* **19**, 594–603 (2013).
67. Damián-Zamacona, S. et al. Cell survival regulation during receptor-mediated endocytosis of chemically-modified lipoproteins associated to the formation of an Amphiphysin 2 (Bin1)/c-Myc complex. *Biochem. Biophys. Res. Commun.* **505**, 365–371 (2018).
68. Mehta, P. R., Brown, A.-L., Ward, M. E. & Fratta, P. The era of cryptic exons: implications for ALS-FTD. *Mol. Neurodegener.* **18**, 16 (2023).
69. Liddelow, S. A. Development of the choroid plexus and blood–CSF barrier. *Front. Neurosci.* **9**, 32 (2015).
70. Serot, J.-M., Béné, M.-C., Foliguet, B. & Faure, G. C. Morphological alterations of the choroid plexus in late-onset Alzheimer’s disease. *Acta Neuropathol.* **99**, 105–108 (2000).
71. Čarna, M. et al. Pathogenesis of Alzheimer’s disease: involvement of the choroid plexus. *Alzheimers Dement.* **19**, 3537–3554 (2023).
72. Cui, J. et al. Inflammation of the embryonic choroid plexus barrier following maternal immune activation. *Dev. Cell* **55**, 617–628 (2020).
73. Wang, Y. et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. *Nat. Immunol.* **13**, 753–760 (2012).
74. Mizuno, T. et al. Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid- β neurotoxicity. *Am. J. Pathol.* **179**, 2016–2027 (2011).
75. Yang, A. C. et al. A human brain vascular atlas reveals diverse mediators of Alzheimer’s risk. *Nature* **603**, 885–892 (2022).
76. Bossaerts, L., Cacace, R. & Van Broeckhoven, C. The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease. *Mol. Neurodegener.* **17**, 31 (2022).
77. Ando, K. et al. PICALM and Alzheimer’s disease: an update and perspectives. *Cells* **11**, 3994 (2022).
78. Kanekiyo, T. & Bu, G. The low-density lipoprotein receptor-related protein 1 and amyloid- β clearance in Alzheimer’s disease. *Front. Aging Neurosci.* **6**, 93 (2014).
79. Chitu, V., Gokhan, Ş., Nandi, S., Mehler, M. F. & Stanley, E. R. Emerging roles for CSF-1 receptor and its ligands in the nervous system. *Trends Neurosci.* **39**, 378–393 (2016).
80. Zuroff, L. R. et al. Effects of IL-34 on macrophage immunological profile in response to Alzheimer’s-related A β ₄₂ assemblies. *Front. Immunol.* **11**, 1449 (2020).
81. Dayon, L. et al. Proteomes of paired human cerebrospinal fluid and plasma: relation to blood–brain barrier permeability in older adults. *J. Proteome Res.* **18**, 1162–1174 (2019).
82. Zlokovic, B. V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. *Nat. Rev. Neurosci.* **12**, 723–738 (2011).
83. Bell, R. D. et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. *Neuron* **68**, 409–427 (2010).
84. Armulik, A. et al. Pericytes regulate the blood–brain barrier. *Nature* **468**, 557–561 (2010).
85. Carrano, A. et al. Neuroinflammation and blood–brain barrier changes in capillary amyloid angiopathy. *Neurodegener. Dis.* **10**, 329–331 (2012).
86. Garcia, F. J. et al. Single-cell dissection of the human brain vasculature. *Nature* **603**, 893–899 (2022).
87. Procter, T. V., Williams, A. & Montagne, A. Interplay between brain pericytes and endothelial cells in dementia. *Am. J. Pathol.* **191**, 1917–1931 (2021).
88. Halliday, M. R. et al. Accelerated pericyte degeneration and blood–brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease. *J. Cereb. Blood Flow Metab.* **36**, 216–227 (2016).
89. Greenberg, S. M. et al. Cerebral amyloid angiopathy and Alzheimer disease—one peptide, two pathways. *Nat. Rev. Neurol.* **16**, 30–42 (2020).
90. Tomassen, J. et al. Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: a monozygotic twin study. *Alzheimers Dement.* **8**, e12346 (2022).
91. Tijms, B. M. et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid- β 1–42 analysis results. *Clin. Chem.* **64**, 576–585 (2018).

92. Mulder, C. et al. Amyloid- β (1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. *Clin. Chem.* **56**, 248–253 (2010).
93. Ingala, S. et al. Application of the ATN classification scheme in a population without dementia: findings from the EPAD cohort. *Alzheimers Dement* **17**, 1189–1204 (2021).
94. Willemsse, E. A. J. et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: the ABIDE project. *Alzheimers Dement.* **10**, 563–572 (2018).
95. Wesenhagen, K. E. J. et al. P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. *Alzheimers Res. Ther.* **14**, 95 (2022).
96. Tesi, N. et al. Centenarian controls increase variant effect sizes by an average twofold in an extreme case–extreme control analysis of Alzheimer's disease. *Eur. J. Hum. Genet.* **27**, 244–253 (2019).
97. Dicks, E. et al. Gray matter network measures are associated with cognitive decline in mild cognitive impairment. *Neurobiol. Aging* **61**, 198–206 (2018).
98. Legdeur, N. et al. Associations of brain pathology, cognitive and physical markers with age in cognitively normal individuals aged 60–102 years. *J. Gerontol. A Biol. Sci. Med. Sci* **75**, 1609–1617 (2020).
99. Lorenzini, L. et al. The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. *Neuroimage Clin.* **35**, 103106 (2022).
100. Plubell, D. L. et al. Extended multiplexing of tandem mass tags (TMT) labeling reveals age and high fat diet specific proteome changes in mouse epididymal adipose tissue. *Mol. Cell. Proteomics* **16**, 873–890 (2017).
101. Zhang, Y. et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. *Neuron* **89**, 37–53 (2016).
102. Rouillard, A. D. et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. *Database* **2016**, baw100 (2016).
103. Otero-Garcia, M. et al. Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer's disease. *Neuron* **110**, 2929–2948 (2022).
104. Modeste, E. S. et al. Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease. *Mol. Neurodegener.* **18**, 48 (2023).
105. Dammer, E. B. et al. Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome. *Alzheimers Res. Ther.* **14**, 174 (2022).
106. Dayon, L. et al. Alzheimer disease pathology and the cerebrospinal fluid proteome. *Alzheimers Res. Ther.* **10**, 66 (2018).
107. Johnson, E. C. B. et al. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. *Nat. Med.* **26**, 769–780 (2020).

Acknowledgements

B.M.T. was funded by the Dutch Research Council (ZonMW) VIDI no. 09150171910068 and the Dutch L'Oréal-UNESCO fellowship 2022 for women in science. P.J.V. was funded by ZonMW Redefining AD no. 733050824, and received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EPAD grant no. 115736; EPND grant no. 101034344) and from the Innovative Medicines Initiative 2 Joint Undertaking under grant no. 101034344 (EPND). The IMI Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the EFPIA, and from the JPND project PPMI (no. 733051111 through ZonMW). L.V. received research support from ZonMW, Alzheimer Nederland Foundation and Dioraphte

Foundation. W.M.v.d.F. is supported by the Pasman foundation. W.M.v.d.F. is the recipient of OTAPA, a collaboration project cofunded by the PPP allowance made available by Health-Holland, Top Sector Life Sciences and Health to stimulate public and private partnerships and Brain Research Center (grant no. LSHM19051). W.M.v.d.F. is the recipient of the JPND-funded E-DADS (ZonMW project no. 733051106). W.M.v.d.F. is the recipient of ABOARD, and N.T. is appointed at ABOARD, which is a public and private partnership receiving funding from ZonMW (no. 73305095007) and Health-Holland, and Top Sector Life Sciences and Health (PPP allowance; no. LSHM20106). W.M.v.d.F., C.E.T. and B.M.T. are recipients of TAP-dementia (www.tap-dementia.nl), funded by ZonMW (no. 10510032120003) in the context of the Onderzoeksprogramma Dementie, which is part of the Dutch National Dementia Strategy. V.V. is supported by the JPND-funded E-DADS project (ZonMW project no. 733051106). F.B. is supported by the National Institute for Health and Care Research Biomedical Research Centre at University College London Hospitals. L.M.R. was funded by a ZonMW Memorabel fellowship (no. 10510022110012). S.L. is the recipient of ZonMW funding (no. 733050512). Genotyping of the Dutch case-control samples was performed in the context of the European Alzheimer DNA biobank funded by the JPco-fuND FP-829-029 (ZonMW project no. 733051061). C.E.T. is supported by the European Commission (Marie Curie International Training Network, grant no. 860197 (MIRIADe), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no. 831434), EPND (IMI 2 Joint Undertaking, grant no. 101034344) and JPND (bPRIDE), National MS Society (Progressive MS Alliance), Alzheimer Association, Health-Holland, the ZonMW, the Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation and Alzheimer Nederland Foundation. C.E.T. is the recipient of ABOARD, which is a public and private partnership receiving funding from ZonMW (no. 73305095007), and Health-Holland and Top Sector Life Sciences and Health (PPP allowance; no. LSHM20106). The research of Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by the Alzheimer Nederland Foundation and VUmc Fund. For part of this work, the Dutch national e-infrastructure was used with support from the SURF Cooperative using grant no. EINF-2044. Mass spectrometry-based proteomic analyses were performed by F.S.B. at the Proteomics Unit at the University of Bergen. This facility is a member of the National Network of Advanced Proteomics Infrastructure, which is funded by the Research Council of Norway (INFRASTRUKTUR-program project no. 295910). Proteomics data have been made available with support from the Alzheimer's Disease Data Initiative (ADDI) and AD Workbench. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author contributions

B.M.T. and P.J.V. conceived and designed the study. O.M. and F.S.B. carried out the proteomic measurements. C.E.T., L.V., E.V. and J.G. carried out the ELISA and biobank measurements. Y.A.L.P., W.M.v.d.F., J.T., A.d.B., K.E.J.W., E.M.V. and L.V. collected the data and carried out the clinical evaluation. B.M.T. and P.J.V. carried out the statistical analysis and drafted the manuscript. F.B., V.V. and L.L. carried out the neuroimaging analyses. H.H., S.v.d.L., L.M.R. and N.T. carried out the genetic analyses. All authors reviewed and edited the manuscript.

Competing interests

P.J.V. and B.M.T. are coinventors on a patent of CSF proteomic subtypes (published under patent no. US2022196683A1, owner VUmc Foundation). E.V. is cofounder of ADx NeuroSciences, while J.G. is an employee of ADx NeuroSciences. F.B. is on the steering committee or data safety monitoring board for Biogen, Merck, ATRI/ACTC and Prothena. He is a consultant for Roche, Celltrion, Rewind Therapeutics, Merck, IXICO, Jansen and Combinostics. He has

research agreements with Merck, Biogen, GE Healthcare and Roche, and he is cofounder and shareholder of Queen Square Analytics LTD. L.V. received consulting fees from Roche and Olink, all paid to Amsterdam UMC. C.E.T. performed contract research for ADx NeuroSciences, AC-Immune, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Siemens, Toyama and Vivoryon. She is editor of *Alzheimer Research and Therapy*, and serves on the editorial boards of *Medidact Neurologie/Springer* and *Neurology: Neuroimmunology & Neuroinflammation*. The remaining authors declare no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s43587-023-00550-7>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s43587-023-00550-7>.

Correspondence and requests for materials should be addressed to Betty M. Tijms.

Peer review information *Nature Aging* thanks the anonymous reviewer(s) for their contribution to the peer review of this work.


Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.


© The Author(s) 2024

¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. ²Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands. ³Proteomics Unit at the University of Bergen, Department of Biomedicine, University of Bergen, Bergen, Norway. ⁴Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. ⁵Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. ⁶Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. ⁷Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. ⁸Amsterdam Neuroscience, Neuroimaging, Amsterdam, the Netherlands. ⁹Neurochemistry Laboratory, Department of Laboratory Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. ¹⁰Delft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands. ¹¹Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. ¹²ADx NeuroSciences, Ghent, Belgium. ¹³Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, UK. ¹⁴Epidemiology & Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. ¹⁵Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands. ¹⁶Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden. ✉e-mail: b.tijms@amsterdamumc.nl




Extended Data Fig. 1 | Trajectories of repeated cognitive test scores over time for AD subtypes. Analyses were stratified according to clinical stage. In all plots the grey line represents the trajectory of the control group (that is, individuals with intact cognition and normal CSF markers). * indicates that the slope differs from zero with $p < 0.05$. a indicates slope different from controls, b indicates

slope different from subtype 1, c indicates slope different from subtype 2, d indicates slope different from subtype 3, e indicates slope different from subtype 4 and f indicates slope different from subtype 5. See Supplementary Table 7 for statistical metrics.




Extended Data Fig. 2 | Trajectories of repeated cognitive scores for subtype 3 individuals without dementia. Grey lines indicate individuals with dementia and subtype 3. MMSE includes one individual with normal cognition (blue line), all other tests include two individuals with MCI (red lines). No statistics were performed for prodementia individuals due to small sample size.



Extended Data Fig. 3 | Comparing subtypes on cortical thickness in dementia stage. β indicates mean cortical thickness in mm, averaged over right and left hemispheres and adjusted for age and sex. **a)** Cortical thickness compared between AD subtypes (in dementia stage) with controls. **b)** Cortical thickness


comparisons between AD subtypes within the dementia stage. Negative values indicate thinner cortex in the subtype indicated in the row as compared to the subtype indicated in the column. Analyses were adjusted for age and sex.

Protein differences between subtypes per clinical stage in Alzheimer's disease (AD)



Extended Data Fig. 4 | Comparing Alzheimer's disease (AD) subtypes on protein levels against controls, plotted separately according to clinical stage. Left for cognitively normal with abnormal amyloid, middle for MCI with abnormal amyloid and right for AD dementia and abnormal amyloid. Plots indicates highly similar subtype patterns, suggesting that protein levels reflect

particular AD related traits. See Supplementary Table 5 columns CY to HU for statistical metrics of subtype comparisons within each clinical stage. All proteins were scaled according to the mean and standard deviation of the control group, such that positive values indicate higher levels than controls, and negative values lower levels than controls.



Extended Data Fig. 5 | Batch correction of TMT experiments. a) Biplot of first two principal components on unnormalized protein abundances have batch effects between TMT experiments as indicated by the non-overlapping circles

that correspond to all 44 TMT experiments. b) Batch effects were successfully removed with the Internal Reference Scaling method as described in the online methods.

Corresponding author(s): Betty TijmsLast updated by author(s): Nov 1, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All mass spec data generated for this study will become available through the ADDI workbench after publication of this manuscript. Other data used in this publication was accessed as described in the methods section.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	Sex was self reported. Numbers on sex are provided in table 1 and supplementary table 1.
Reporting on race, ethnicity, or other socially relevant groupings	Not applicable
Population characteristics	Relevant characteristics were reported in table 1 and supplementary table 1
Recruitment	REcruitment was reported in the methods section at p10 (and in publications cited there)
Ethics oversight	All studies were approved by the ethical Committee of the Amsterdam UMC, location VUmc, the Biobank Research Ethics Committee of the Amsterdam UMC, location VUmc, and the Ethical Committee of the University of Norway

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Our pilot study in 284 subjects detected the presence of three AD pathophysiological subtypes (distribution 50%, 25% and 25%) that showed differences in over 100 proteins with a power of 80% and with 1-sided testing at p=0.05, suggesting that subgroups should have a minimum n=30 to discover meaningful subtype differences. Data-driven approaches require a sample size of at least n=50 to discover reproducible subtypes.[52] We performed simulation study with parameters estimated from our pilot data.[52] Increasing the sample size to n=650 and keeping the number of proteins stable resulted in discovery of an additional fourth subtype. Next we simulated the effect of the increase in number of proteins to 1000, with correlation structures to represent 5 additional subtypes (increasing the number of subtypes to 8). The sample size of 650 subjects was able detect all these additional subtypes, while in our pilot sample size (n=284) only one of these additional subtypes was detected. Together these simulation analyses suggest that our sample size of 650 substantially increases power to detect more fine-grained AD subtypes.
Data exclusions	One individual was excluded for whom proteomics was measured, but had normal CSF markers and appeared later to have a diagnosis of PPA (and so could not serve as a control)
Replication	We replicated the new subtypes in 6 independent cohorts with CSF TMT proteomics available, as described in the methods section at p16
Randomization	Samples were randomised across TMT plex channels
Blinding	Researchers who measured TMT proteomics were blinded to diagnosis. Researchers performing statistical analyses were not blinded to diagnosis, because diagnosis was required for subgroup analyses.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

- n/a Involved in the study
- Antibodies
- Eukaryotic cell lines
- Palaeontology and archaeology
- Animals and other organisms
- Clinical data
- Dual use research of concern
- Plants

- n/a Involved in the study
- ChIP-seq
- Flow cytometry
- MRI-based neuroimaging

Antibodies

- Antibodies used
- Validation

Magnetic resonance imaging

Experimental design

- Design type
- Design specifications
- Behavioral performance measures

Acquisition

- Imaging type(s)
- Field strength
- Sequence & imaging parameters
- Area of acquisition
- Diffusion MRI Used Not used

Preprocessing

- Preprocessing software
- Normalization
- Normalization template
- Noise and artifact removal
- Volume censoring

Statistical modeling & inference

- Model type and settings
- Effect(s) tested
- Specify type of analysis: Whole brain ROI-based Both
- Anatomical location(s)

Statistic type for inference

n.a.

(See [Eklund et al. 2016](#))

Correction

These were post hoc analyses

Models & analysis

n/a | Involved in the study

Functional and/or effective connectivity

Graph analysis

Multivariate modeling or predictive analysis

Graph analysis

detailed in methods section at p14